Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation

Management of acute respiratory distress syndrome (ARDS) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a challenge for the staff on intensive-care units (ICU’s) around the world. Many of these patients are treated with invasive ventilation. Sometimes, the occurrence...

Full description

Saved in:
Bibliographic Details
Main Authors: Julian Umlauf, Stefanie Eilenberger, Oliver Spring
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Case Reports in Critical Care
Online Access:http://dx.doi.org/10.1155/2022/6559385
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849469523075268608
author Julian Umlauf
Stefanie Eilenberger
Oliver Spring
author_facet Julian Umlauf
Stefanie Eilenberger
Oliver Spring
author_sort Julian Umlauf
collection DOAJ
description Management of acute respiratory distress syndrome (ARDS) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a challenge for the staff on intensive-care units (ICU’s) around the world. Many of these patients are treated with invasive ventilation. Sometimes, the occurrence of pneumothorax and/or pneumomediastinum can complicate the course of the disease because initiation of invasive ventilation might be fatal in those patients. Venovenous extracorporal membrane oxygenation (vv-ECMO) is increasingly used to prevent patients with severe ARDS from hypoxia. However, clear recommendations for or against the initiation of vv-ECMO in awake patients are currently lacking. We present the case of a 42-year-old patient with COVID-19-associated severe ARDS, pneumothorax, and pneumomediastinum. To preserve sufficient oxygenation and to avoid invasive ventilation, we implanted a vv-ECMO while the patient was awake. The patient recovered and was discharged home 41 days after transfer to our hospital. We therefore suggest that awake implantation of vv-ECMO might be useful in a subgroup of patients with severe ARDS caused by SARS-CoV-2. However, further evidence is needed to verify our hypothesis.
format Article
id doaj-art-fd4c4ea6edd24da9a18253f24c63a6c8
institution Kabale University
issn 2090-6439
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Case Reports in Critical Care
spelling doaj-art-fd4c4ea6edd24da9a18253f24c63a6c82025-08-20T03:25:26ZengWileyCase Reports in Critical Care2090-64392022-01-01202210.1155/2022/6559385Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO ImplantationJulian Umlauf0Stefanie Eilenberger1Oliver Spring2Department of Anaesthesia and Surgical Intensive Care MedicineDepartment of Anaesthesia and Surgical Intensive Care MedicineDepartment of Anaesthesia and Surgical Intensive Care MedicineManagement of acute respiratory distress syndrome (ARDS) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still a challenge for the staff on intensive-care units (ICU’s) around the world. Many of these patients are treated with invasive ventilation. Sometimes, the occurrence of pneumothorax and/or pneumomediastinum can complicate the course of the disease because initiation of invasive ventilation might be fatal in those patients. Venovenous extracorporal membrane oxygenation (vv-ECMO) is increasingly used to prevent patients with severe ARDS from hypoxia. However, clear recommendations for or against the initiation of vv-ECMO in awake patients are currently lacking. We present the case of a 42-year-old patient with COVID-19-associated severe ARDS, pneumothorax, and pneumomediastinum. To preserve sufficient oxygenation and to avoid invasive ventilation, we implanted a vv-ECMO while the patient was awake. The patient recovered and was discharged home 41 days after transfer to our hospital. We therefore suggest that awake implantation of vv-ECMO might be useful in a subgroup of patients with severe ARDS caused by SARS-CoV-2. However, further evidence is needed to verify our hypothesis.http://dx.doi.org/10.1155/2022/6559385
spellingShingle Julian Umlauf
Stefanie Eilenberger
Oliver Spring
Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
Case Reports in Critical Care
title Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
title_full Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
title_fullStr Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
title_full_unstemmed Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
title_short Successful Treatment of a Patient with COVID-19-Induced Severe ARDS, Pneumothorax, and Pneumomediastinum with Awake vv-ECMO Implantation
title_sort successful treatment of a patient with covid 19 induced severe ards pneumothorax and pneumomediastinum with awake vv ecmo implantation
url http://dx.doi.org/10.1155/2022/6559385
work_keys_str_mv AT julianumlauf successfultreatmentofapatientwithcovid19inducedsevereardspneumothoraxandpneumomediastinumwithawakevvecmoimplantation
AT stefanieeilenberger successfultreatmentofapatientwithcovid19inducedsevereardspneumothoraxandpneumomediastinumwithawakevvecmoimplantation
AT oliverspring successfultreatmentofapatientwithcovid19inducedsevereardspneumothoraxandpneumomediastinumwithawakevvecmoimplantation